Modulating inflammatory signaling pathways, such as NF-κB, may be a novel therapeutic target for desmosomal-mediated cardiomyopathy, as recently demonstrated in a mouse model harboring homozygous mutations in DSG2 (26). The gene discussed is NFKB1; the disease is cardiomyopathy.